Ardelyx is developing novel, minimally-systemic phosphate transport inhibitors targeting the intestinal phosphate transporter NaP2b for the treatment of phosphorus disorders associated with Chronic Kidney Disease (CKD) and end-stage renal disease (ESRD). Ardelyx's RDX002 program has identified several unique classes of NaP2b inhibitors.
Such compounds reduce phosphate absorption in the gut and demonstrate results that are, at a minimum, comparable to commercial phosphate binders but at a much lower dose. Ardelyx has generated data that demonstrates an additive effect of its NaP2b inhibitors when combined with currently available phosphate binders.
This class of compounds has the potential to treat secondary hyperparathyroidism and reduce morbidity and mortality risk in the CKD population, representing 20 million people in the US alone.